Stock Price & Analysis

The S1 support level for AURA Stock is $7.42 ,The R1 resistant level for AURA Stock is $8.05.

As of the end of day on 2025-02-25, the price of AURA Stock was $7.38.

The target price for AURA Stock according to analyst rating is 22.00, with the highest price target at 23.00 and the lowest at 21.00. Analysts have a Moderate Buy rating on AURA Stock overall.

The market cap of AURA is $368.1M.

Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. It is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and activation of a secondary immune mediated response. Its lead candidate, bel-sar, is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. Bel-sar consists of a human papillomavirus (HPV)-derived virus-like particle (VLP), conjugated to hundreds of infrared laser-activated molecules. It is evaluating the bel-sar in a Phase III CoMpass trial for the first line treatment of early-stage choroidal melanoma.

AURA has a total of 88 employees.